Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: REPL stock price vs AMAT: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at AMAT's multiple
Needs Revenue / share, AMAT P/S.
Implied fair value · at REPL's multiple
Needs REPL P/S.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Higher is better
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
REPLIMUNE GROUP, INC. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
APPLIED MATERIALS INC /DE · implied price per share
Bear
$93.19
Base
$109.17
Bull
$129.97
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMGEN INC
REPL vs AMGN
INCYTE CORP
REPL vs INCY
Blueprint Medicines Corp
REPL vs BPMC
Adaptive Biotechnologies Corp
REPL vs ADPT
LAM RESEARCH CORP
REPL vs LRCX
ASML HOLDING NV
REPL vs ASML
TERADYNE, INC
REPL vs TER
MKS INSTRUMENTS INC
REPL vs MKSI
KLA CORP
REPL vs KLAC
SKYWORKS SOLUTIONS, INC.
REPL vs SWKS
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe REPL can materially improve profitability and quality scores from today’s weak baseline, then a cautious hold or selective buy could make sense because the stock is trading within its historical range and the downside gap is not obvious from the limited data provided.
REPL’s current price of $11.58 sits inside its historical band of $10.42 to $12.74, suggesting no obvious valuation dislocation from the data provided. Unlike AMAT, which has clearly defined revenue and earnings power, REPL lacks enough reported operating metrics here to support a clean relative valuation gap.
Supporting Metrics
